Sensei Biotherapeutics (NASDAQ:FTH) Stock Price Down 4.4% - Here's Why

Key Points

• Sensei Biotherapeutics shares fell 4.4% to about $32.34 in thin trading, with volume down 97% from the average daily level.
• Analysts remain broadly optimistic, giving the stock a “Moderate Buy” consensus and an average price target of $55, despite one sell rating.
• The company beat quarterly EPS expectations, while insiders purchased nearly $1.2 million of stock over the past quarter; institutional investors own 10.5% of shares.

Sensei Biotherapeutics, Inc. (NASDAQ:FTH - Get Free Report) dropped 4.4% on Monday . The company traded as low as $32.50 and last traded at $32.3350. Approximately 5,424 shares were traded during mid-day trading, a decline of 97% from the average daily volume of 211,740 shares. The stock had previously closed at $33.84.

Wall Street Analysts Forecast Growth

FTH has been the topic of a number of analyst reports. Loop Capital set a $50.00 price objective on shares of Sensei Biotherapeutics in a research note on Thursday, May 28th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Sensei Biotherapeutics in a research note on Thursday, June 4th. Citizens Jmp initiated coverage on shares of Sensei Biotherapeutics in a report on Monday, July 20th. They issued an "outperform" rating and a $51.00 price objective on the stock. Weiss Ratings initiated coverage on shares of Sensei Biotherapeutics in a research report on Wednesday, June 17th. They issued a "sell (d-)" rating for the company. Finally, Oppenheimer started coverage on Sensei Biotherapeutics in a research report on Tuesday, July 28th. They set an "outperform" rating and a $60.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $55.00.

Sensei Biotherapeutics Trading Down 5.7%

The company has a 50-day moving average of $28.53. The company has a market capitalization of $824.81 million, a price-to-earnings ratio of -0.23 and a beta of -0.25.

Sensei Biotherapeutics (NASDAQ:FTH - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($5.04) by $2.20. As a group, sell-side analysts expect that Sensei Biotherapeutics, Inc. will post -13.18 EPS for the current year.

Insider Transactions at Sensei Biotherapeutics

In other news, CFO Brian C. Stephenson purchased 9,391 shares of the firm's stock in a transaction that occurred on Wednesday, June 24th. The stock was acquired at an average cost of $26.13 per share, for a total transaction of $245,386.83. Following the completion of the purchase, the chief financial officer owned 26,804 shares of the company's stock, valued at approximately $700,388.52. This trade represents a 53.93% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Anand Kiran Parikh acquired 2,806 shares of the stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average cost of $19.76 per share, with a total value of $55,446.56. Following the completion of the acquisition, the chief executive officer owned 764,234 shares of the company's stock, valued at $15,101,263.84. The trade was a 0.37% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased 49,494 shares of company stock valued at $1,188,822 over the last quarter. Insiders own 7.00% of the company's stock.

Institutional Investors Weigh In On Sensei Biotherapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC lifted its stake in Sensei Biotherapeutics by 10.6% during the fourth quarter. Renaissance Technologies LLC now owns 11,516 shares of the company's stock worth $123,000 after purchasing an additional 1,100 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Sensei Biotherapeutics by 10,692.5% during the first quarter. Bank of America Corp DE now owns 33,025 shares of the company's stock worth $1,041,000 after purchasing an additional 32,719 shares during the period. Alyeska Investment Group L.P. bought a new position in shares of Sensei Biotherapeutics in the 2nd quarter worth about $3,610,000. Stempoint Capital LP acquired a new position in shares of Sensei Biotherapeutics in the 1st quarter valued at about $4,188,000. Finally, Vivo Capital LLC acquired a new position in shares of Sensei Biotherapeutics in the 1st quarter valued at about $22,758,000. 10.50% of the stock is owned by institutional investors and hedge funds.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source